UBS Maintains Buy on Elevance Health, Raises Price Target to $605
Portfolio Pulse from Benzinga Newsdesk
UBS analyst A.J. Rice maintains a Buy rating on Elevance Health (NYSE:ELV) and raises the price target from $585 to $605.
April 19, 2024 | 2:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS maintains a Buy rating on Elevance Health and raises the price target to $605.
The upgrade in the price target by UBS reflects a positive outlook on Elevance Health's stock, suggesting confidence in the company's future performance. This is likely to be viewed positively by investors, potentially leading to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100